ACcomplisH: A Phase 2, multicenter, double-blind, randomized, placebo-controlled, dose escalation trial evaluating safety, efficacy, and pharmacokinetics of subcutaneous doses of TransCon CNP administered once weekly for 12 months in prepubertal children with achondroplasia
This Study is
No Longer Enrolling
Details
Age
Child
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Study ID
Protocol Number: 20-0142
More information available at ClinicalTrials.gov: NCT04085523
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers